Endocrine Abstracts

Introduction: Acromegaly is a rare chronic disorder caused by growth hormone hypersecretion due to GH-producing pituitary adenoma. Surgery is the first-line treatment modality. However, patients with severe cardiac involvement are high-risk candidates for pituitary surgery. These patients may benefit from rapid preoperative biochemical control of acromegaly. There is emerging evidence of efficacy of pegvisomant, a GH-receptor antagonist, (either alone or in combination with so...

Background, aims: Acromegaly is caused by excessive growth hormone (GH) secretion, usually by a pituitary adenoma. Surgical removal of the GH-producing adenoma is the most effective treatment. Drug treatment is second-line option. Earlier work suggested Soluble (s)Klotho levels to be a supplementary biomarker to IGF-1. We tested whether IGF-1 and sKlotho serum levels show a concomitant reduction under medical treatment. If yes, is the extent of reduction in serum IGF-1 and sKl...

Background and aims: Recommendations for the management of pregnancies in patients with adrenal insufficiency (AI) are scarce. The aim of this study was to analyse current clinical approaches in seventeen specialized centers across Europe with a particular focus on maternal and fetal outcome.Patients: 95 pregnancies in 86 patients with AI of different aetiology [Addison’s disease (n=37), secondary AI (n=22), congenital adrenal hype...